Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2).
BACKGROUND
Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies against coagulation factor VIII and characterized by spontaneous hemorrhage in patients with no previous family or personal history of bleeding. Although data on several AHA cohorts have been collected, limited information is available on the optimal management of AHA.


OBJECTIVE
The European Acquired Hemophilia Registry (EACH2) was established to generate a prospective, large-scale, pan-European database on demographics, diagnosis, underlying disorders, bleeding characteristics, treatment and outcome of AHA patients.


RESULTS
Five hundred and one (266 male, 235 female) patients from 117 centers and 13 European countries were included in the registry between 2003 and 2008. In 467 cases, hemostasis investigations and AHA diagnosis were triggered by a bleeding event. At diagnosis, patients were a median of 73.9 years. AHA was idiopathic in 51.9%; malignancy or autoimmune diseases were associated with 11.8% and 11.6% of cases. Fifty-seven per cent of the non-pregnancy-related cases were male. Four hundred and seventy-four bleeding episodes were reported at presentation, and hemostatic therapy initiated in 70.5% of patients. Delayed diagnosis significantly impacted treatment initiation in 33.5%. Four hundred and seventy-seven patients underwent immunosuppression, and 72.6% achieved complete remission.


CONCLUSIONS
Representing the largest collection of consecutive AHA cases to date, EACH2 facilitates the analysis of a variety of open questions in AHA.
Division of Hematology and Hemostasis, Department of Medicine 1, Medical University of Vienna, Vienna, Austria. paul.knoebl@meduniwien.ac.at
P
P
Knoebl
P
P
Marco
F
F
Baudo
P
P
Collins
A
A
Huth-Kühne
L
L
Nemes
F
F
Pellegrini
L
L
Tengborn
H
H
Lévesque
D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood; D016009:Chi-Square Distribution; D005060:Europe / Q000453:epidemiology; D005169:Factor VIII / Q000276:immunology; D005260:Female; D006467:Hemophilia A / Q000175:diagnosis / Q000276:immunology / Q000401:mortality / Q000628:therapy; D006470:Hemorrhage / Q000175:diagnosis / Q000276:immunology / Q000401:mortality / Q000628:therapy; D006489:Hemostatic Techniques; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011446:Prospective Studies; D012042:Registries; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
D001323:Autoantibodies; D007166:Immunosuppressive Agents; D005169:Factor VIII